Becker's Healthcare April 4, 2024
A small study has found lixisenatide, a GLP-1 made by Sanofi, may slow the progression of Parkinson’s disease, according to findings published April 3 in The New England Journal of Medicine.
The phase 2 trial involved 156 people who had been diagnosed with Parkinson’s less than three years before the study began. Half of the participants were assigned to a placebo group, while the other half were given lixisenatide. Researchers followed the participants for one year. Those in the placebo group were more likely to report that their symptoms worsened during that time, the findings showed.
More than half of the participants who were in the lixisenatide group reported gastrointestinal side effects, which may be due...
Today's Sponsors
Today's Sponsor